Quintiles Transitional Holdings Inc. (NYSE:Q) had its target price lifted by Argus from $98.00 to $104.00 in a research note issued to investors on Monday. The firm currently has a buy rating on the medical research company’s stock.
A number of other research analysts also recently issued reports on Q. Credit Suisse Group restated an outperform rating and set a $96.00 price target (up previously from $94.00) on shares of Quintiles Transitional Holdings in a research note on Tuesday, June 6th. Citigroup Inc. restated a neutral rating and set a $96.00 price target (up previously from $87.00) on shares of Quintiles Transitional Holdings in a research note on Wednesday, June 28th. Robert W. Baird upgraded Quintiles Transitional Holdings from an underperform rating to a neutral rating and raised their price target for the stock from $76.00 to $93.00 in a research note on Friday, July 7th. Barclays PLC restated an overweight rating and set a $98.00 price target (up previously from $90.00) on shares of Quintiles Transitional Holdings in a research note on Monday, July 17th. Finally, Zacks Investment Research upgraded Quintiles Transitional Holdings from a hold rating to a buy rating and set a $101.00 price target on the stock in a research note on Thursday, July 27th. Eleven investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $92.44.
Shares of Quintiles Transitional Holdings (Q) opened at 94.22 on Monday. The company has a 50-day moving average price of $93.80 and a 200-day moving average price of $86.86. Quintiles Transitional Holdings has a 12 month low of $70.10 and a 12 month high of $99.95. The stock has a market cap of $20.40 billion, a price-to-earnings ratio of 273.10 and a beta of 0.63.
Quintiles Transitional Holdings (NYSE:Q) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.04. The firm had revenue of $1.97 billion for the quarter, compared to the consensus estimate of $1.96 billion. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. The firm’s quarterly revenue was up 68.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.93 EPS. On average, analysts expect that Quintiles Transitional Holdings will post $4.58 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/quintiles-transitional-holdings-inc-q-price-target-increased-to-104-00-by-analysts-at-argus/1657237.html.
In related news, insider Kevin C. Knightly sold 20,000 shares of Quintiles Transitional Holdings stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $90.28, for a total value of $1,805,600.00. Following the sale, the insider now directly owns 46,826 shares in the company, valued at $4,227,451.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Cpp Investment Board Private H sold 6,748,026 shares of Quintiles Transitional Holdings stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $94.87, for a total value of $640,185,226.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,142,302 shares of company stock worth $1,356,515,722. Company insiders own 6.40% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Fiduciary Trust Co. acquired a new position in Quintiles Transitional Holdings during the second quarter worth $105,000. Global X Management Co. LLC raised its holdings in shares of Quintiles Transitional Holdings by 30.8% in the first quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock worth $118,000 after acquiring an additional 346 shares during the last quarter. GWM Advisors LLC acquired a new position in shares of Quintiles Transitional Holdings in the second quarter worth $122,000. Korea Investment CORP raised its holdings in shares of Quintiles Transitional Holdings by 142.5% in the second quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock worth $123,000 after acquiring an additional 805 shares during the last quarter. Finally, Archford Capital Strategies LLC acquired a new position in shares of Quintiles Transitional Holdings in the first quarter worth $160,000. 91.34% of the stock is owned by hedge funds and other institutional investors.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with our FREE daily email newsletter.